Navigation Links
Syndax's Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer
Date:9/11/2013

WALTHAM, Mass., Sept. 11, 2013 /PRNewswire/ -- Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy. Entinostat is an investigational histone deacetylase inhibitor (HDACi) set to begin Phase 3 testing in combination with exemestane in postmenopausal women with metastatic ER+ breast cancer who have progressed on hormonal therapy.

The Breakthrough Therapy designation for entinostat is based on data from the completed Phase 2 ENCORE 301 study, in which entinostat was shown to extend both progression-free survival and overall survival when added to exemestane in postmenopausal women with ER+ metastatic breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor and with a very acceptable tolerability profile. A Phase 3 trial, planned to begin enrolling patients in the first quarter of 2014 is currently being developed by the ECOG-ACRIN Cancer Research Group, which would conduct the study under the sponsorship of the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI).

"The FDA's decision to designate entinostat a Breakthrough Therapy is important validation of the drug's therapeutic potential in women with advanced breast cancer," said Arlene M. Morris, Syndax's chief executive officer. "Currently, women with ER+ breast cancer who have progressed on hormonal therapy have limited therapeutic options. Entinostat's epigenetic mechanism may reverse resistance to hormonal therapy, delaying the need for toxic chemotherapeutic agents and improving survival when given in combination with a
'/>"/>

SOURCE Syndax Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
2. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
3. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
4. NextDocs Receives $13.5 Million in Funding to Fuel Expansion
5. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
6. Unique New PIR Knee System Receives CE Mark
7. EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
8. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
9. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
10. HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
11. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Mass. , Aug. 28, 2014  Decision ... system market will grow strongly through 2022 at ... percent. This will be largely supported by strong ... will increase demand for imaging procedures. The Indian ... allow more facilities to purchase or upgrade diagnostic ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Landscape Poland " an essential source of information ... market and provides insights into the demographic, regulatory, ... report provides valuable insights into the trends and ...
(Date:8/28/2014)... Japan , Aug. 28, 2014 ... of the post-marketing commitment and submissions of data ... including the United States ... Medicines Agency (EMA) and the Japanese Ministry of ... Pharmaceuticals and Medical Devices Agency (PMDA) for pioglitazone ...
Breaking Medicine Technology:Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 2Indian Diagnostic Imaging System Market Will Grow at 6 Percent Annually Through 2022 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6
(Date:8/29/2014)... 29, 2014 Many Americans are diagnosed ... diabetes type 2 at bay, patients should consider this ... the necessary lifestyle changes. While some diabetes risk factors ... advanced age, or belonging to certain ethnic groups, there ... their weight. Carrying extra pounds, especially in the abdomen, ...
(Date:8/29/2014)... Scientists from four European countries say ... correlates with overall survival of mesothelioma. Surviving Mesothelioma has ... Click here to read it now. , Doctors ... cases of 523 mesothelioma patients who were ... [progression-free survival at 18 weeks after treatment] was strongly ...
(Date:8/29/2014)... 2014 Hep-Lock IV lines are often ... difficult to keep in place comfortably. "I saw a ... discomfort caused by medical tape," said an inventor from ... secure hep-lock IV lines." , The patent-pending IV Ease ... which avoids irritated skin and allergic reactions. It also ...
(Date:8/29/2014)... 29, 2014 A sensor measures ... data, which are used by various industries. Mobile ... and fitness devices to measure various body parameters. ... assist in regular patient monitoring. This would help ... treatment results. Sensors help in gathering patient health-related ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 In 2014, ... physicians retiring, merging or selling their practices. The Deloitte’s ... are likely to retire earlier than planned in the ... most U.S physicians are concerned about the future of ... market. In general, physicians are cynical and worried about ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 3Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2Health News:Mobile Health and Fitness Sensor Market Growing at 40.29% CAGR by 2018 Forecasts a New Report at ReportsnReports.com 2Health News:Mobile Health and Fitness Sensor Market Growing at 40.29% CAGR by 2018 Forecasts a New Report at ReportsnReports.com 3Health News:Mobile Health and Fitness Sensor Market Growing at 40.29% CAGR by 2018 Forecasts a New Report at ReportsnReports.com 4Health News:Mobile Health and Fitness Sensor Market Growing at 40.29% CAGR by 2018 Forecasts a New Report at ReportsnReports.com 5Health News:Planning for Retiring, Selling, or Closing Down the Practice? Help is at Hand 2Health News:Planning for Retiring, Selling, or Closing Down the Practice? Help is at Hand 3Health News:Planning for Retiring, Selling, or Closing Down the Practice? Help is at Hand 4
... Ill., March 11 Citing concerns,about the spread ... and,ecological damage, Dr. Gail Golab, PhD, DVM, director ... Division, spoke on the,dangers of nonhuman primates kept ... of Representatives Committee on Natural Resources., The ...
... rates, but one expert urges caution , , TUESDAY, ... specialized hospitals improved survival time for ovarian cancer patients, ... researchers examined data on 8,621 ovarian cancer patients treated ... women, 40 percent were treated in general hospitals, 41 ...
... Swiss study found standard infection control was just ... News) -- Universal screening for a common antibiotic-resistant ... at reducing the rate of hospital-acquired infections in ... bacteria, methicillin-resistant Staphylococcus aureus (MRSA), is ...
... Greatest burden falls on African-American adolescents, CDC researchers find, ... 3 million teenaged girls have at least one sexually ... The most severely affected are African-American teens. In fact, ... compared with 20 percent of white teenaged girls. , ...
... nurses,and other healthcare workers in Ohio saw their dreams ... Association flooded the state,with hostile organizers and bombarded workers ... them to vote against the union., In the ... of the,AFL-CIO, the workers have for now called off ...
... Current recommendations for weight gain during pregnancy developed ... should be revised, according to an internationally recognized obesity ... and womens health at Saint Louis University. , The ... research on obesity during pregnancy, appears in the March ...
Cached Medicine News:Health News:AVMA Urges Outlawing Trafficking of Chimps, Monkeys and Nonhuman Primates and Pets 2Health News:Specialized Care for Ovarian Cancer Improves Outcomes 2Health News:Universal Screening for MRSA in Hospitals Made Little Difference 2Health News:Universal Screening for MRSA in Hospitals Made Little Difference 3Health News:One in 4 Teen Girls Has a Sexually Transmitted Disease 2Health News:One in 4 Teen Girls Has a Sexually Transmitted Disease 3Health News:SEIU: Thousands of Ohio Nurses and Other Healthcare Employees Denied a Voice at Work After Vicious Union-Busting Campaign by the California Nurses Association 2Health News:Revise guidelines for weight gain during pregnancy, says Saint Louis U. obstetrician 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: